| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $60.4M | — | +45.1% |
| SG&A Expense | $15.2M | — | +27.5% |
| Operating Income | -$45.6M | — | +14.8% |
| Pre-tax Income | -$69.0M | — | -54.1% |
| Income Tax | $0 | — | +100.0% |
| Net Income | -$69.0M | — | -54.1% |
| EPS (Diluted) | -$0.74 | — | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $97.2M | +13.4% | +100.4% |
| Current Assets | $764.0M | -1.8% | +34.1% |
| Total Assets | $764.0M | -1.8% | +34.1% |
| Current Liabilities | $85.2M | +45.1% | +20.5% |
| Total Liabilities | $93.1M | +48.9% | +6.9% |
| Stockholders' Equity | $670.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$57.4M | — | -40.0% |
| Investing Cash Flow | $56.6M | — | — |
| Financing Cash Flow | $12.3M | — | +9704.0% |
| +39.0% |